---
layout: default
title: Insulin Glargine
parent: Model Prediction Only (L5)
nav_order: 478
evidence_level: L5
indication_count: 10
---

# Insulin Glargine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Insulin Glargine: From Diabetes Mellitus to Autoimmune Oophoritis

## One-Sentence Summary

Insulin glargine is a long-acting insulin analogue, used to control blood glucose in diabetes mellitus.
The TxGNN model predicts it may be effective for **autoimmune oophoritis**, but there are currently **0 clinical trials** and **0 publications** supporting this specific prediction.
The high score reflects a network association, not clinical evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the Evidence Pack (insulin glargine is generally used for diabetes mellitus) |
| Predicted New Indication | Autoimmune oophoritis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 9 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available. Insulin glargine is a basal insulin analogue whose efficacy in diabetes is well established. Nothing in the data shows a mechanism that would apply to autoimmune oophoritis.

The only plausible connection is indirect. Autoimmune oophoritis can co-occur with autoimmune polyglandular syndromes that include type 1 diabetes. In those patients insulin treats the diabetes, not the ovarian inflammation. The prediction therefore most likely reflects proximity in the knowledge graph rather than a therapeutic effect on the ovary.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 02441829 | TOUJEO SOLOSTAR |
| 02294338 | LANTUS |
| 02461528 | BASAGLAR |
| 02245689 | LANTUS |
| 02493373 | TOUJEO DOUBLESTAR |

The Evidence Pack lists 5 of the 9 authorizations and does not include dosage form or approved indication text for them.

---

## Safety Considerations

Please refer to the package insert for safety information.

No drug interaction records were found in the queried data. One point from the prediction data: localized lipodystrophy (lipoatrophy or lipohypertrophy) is a known adverse effect of repeated subcutaneous insulin injection.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the model score. There are no trials or publications, and the plausible link runs through comorbid diabetes, which insulin treats but which is not the target disease.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Original approved indication text for the Canadian licenses
- Any direct clinical or preclinical evidence of insulin glargine in autoimmune oophoritis

**Other predicted candidates (for context):**

| Candidate | Score | Evidence Level | Recommendation | Note |
|------|------|------|------|------|
| Pancreatic agenesis | 99.43% | L4 | Research Question | Insulin replacement is biologically coherent, but the 6 retrieved publications are indirect (reviews, a MODY5 case report, veterinary reports). This may be an existing use rather than true repurposing. |
| Thiamine-responsive dysfunction syndrome | 99.61% | L5 | Hold | Insulin would manage only the diabetic component, not the underlying transporter defect. |
| Focal stiff limb syndrome and classic stiff person syndrome | 99.60% | L5 | Hold | Association through anti-GAD65 autoimmunity and comorbid type 1 diabetes; no effect of insulin on the neurological syndrome is known. |
| Opsismodysplasia | 99.59% | L5 | Hold | Speculative link via SHIP2 (INPPL1) in insulin signaling; no supporting evidence. |
| Localized lipodystrophy conditions (4 entries) | 99.34–99.42% | L5 | Hold | These likely reflect insulin's known injection-site adverse effect, not a therapeutic signal. |

*These results are for research reference only and do not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

